AL AMYLOIDOSIS
Clinical trials for AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody therapy targets Hard-to-Treat AL amyloidosis
Disease control TerminatedThis trial aimed to test an experimental drug called CM-336 for people with AL amyloidosis that has returned, not responded to treatment, or only partially responded after initial therapy. The drug works by helping the immune system attack and destroy harmful cells. However, the …
Matched conditions: AL AMYLOIDOSIS
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 17, 2026 03:12 UTC
-
New antibody could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 125 people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove those protein deposits. The goal is to see if it helps people live …
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 03:11 UTC
-
New hope for amyloidosis patients: Long-Term safety study of AT-02 underway
Disease control OngoingThis study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Attralus, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:54 UTC
-
New combo therapy offers hope for hard-to-treat amyloidosis patients
Disease control OngoingThis study tests a combination of three drugs—daratumumab, pomalidomide, and dexamethasone—in 15 adults with AL amyloidosis whose disease has returned or not responded after prior treatment including daratumumab. The goal is to see if this triple therapy leads to more complete re…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Promising antibody tackles rare blood disease
Disease control OngoingThis early-stage trial tests a drug called isatuximab in 11 people with a rare, high-risk blood disease called AL amyloidosis. The goal is to see if the drug is safe and helps control the disease by stopping abnormal cells from growing. Participants receive the drug upfront, and …
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
New hope for rare disease: maintenance drug aims to delay relapse
Disease control OngoingThis study tests whether the chemotherapy drug ixazomib, given as maintenance therapy, can help control AL amyloidosis and delay or prevent the disease from coming back. Seventeen adults who have already completed initial treatment are taking ixazomib to see if it improves event-…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New drug could clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in 281 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs like the heart and kidneys. The drug aims to remove these protein deposits, potentially helping patients live longer and avoid heart-…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 02, 2026 11:58 UTC
-
New drug aims to reduce pain and fatigue after stem cell transplant in older patients
Symptom relief OngoingThis study tests whether a drug called siltuximab can reduce symptoms like weakness, fatigue, nausea, and pain after a stem cell transplant in patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein linked to inflammation, which may help patients re…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 16, 2026 12:50 UTC